Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
97.80    0.00 (0.00%)
Bid:
82.00
Ask:
0.00
Spread: 18.80 (22.927%)
Market Cap: £160.34m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q1 2022 trading update

28 Apr 2022 07:00

RNS Number : 6129J
Synthomer PLC
28 April 2022
 

28th April 2022

 

Synthomer plc

 

Q1 2022 trading update

 

Encouraging start to the year with full year outlook unchanged

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2022.

 

Q1 Trading

 

The Group has had an encouraging start to the year. All businesses were ahead or in line with strong Q1 2021 results excluding Performance Elastomers where NBR continues to normalise relative to an exceptional 2021 performance.

Functional Solutions

Functional Solutions has continued to see very positive trading in the first quarter of 2022. Our consumer facing and industrial end markets have remained strong with raw material and cost inflation successfully passed through to customers. Volumes and unit margins were ahead of the comparative period supported by the ongoing revenue synergies from OMNOVA and the full utilisation of low cost capacity in Europe and the US.

Performance Elastomers

 

NBR margins and volumes continue to stabilise in line with our expectations following high inventory levels of medical gloves and reduced demand due to the easing of the COVID 19 pandemic. Consistent with previous guidance, we expect trading conditions in NBR to normalise by the end of H1 with market growth returning to 2019 levels in H2 2022.

 

Conditions in our SBR business remain robust with better capacity utilisation following the closure of our Oulu site during Q1 2021 as a part of our European SBR network rationalisation programme. We have also seen firmer margins across all significant end markets relative to the comparative period.

Industrial Specialities

Industrial Specialities has had a good start to the year relative to a strong comparative with volumes and unit margins ahead in most segments including industrial and consumer facing markets.

Acrylate Monomers

Acrylate Monomers continues to benefit from the extended period of strong demand and industry supply issues leading to an uplift in unit margins and higher profitability relative to Q1 2021.

Adhesive Technologies

Synthomer completed the $1bn acquisition of Eastman's Adhesive Resins business on 1st April. The business has a leading position in the global adhesives market which is exposed to attractive end-markets with resilient growth fundamentals. Its portfolio takes Synthomer into more specialised, more global and higher growth segments.

Proforma Leverage

 

Proforma net debt:EBITDA leverage as at 1st April 2022 was 1.9x. This reflects the consideration paid for Adhesive Technologies, the expected seasonal investment in working capital and higher raw material prices.

 

FY expectations unchanged

 

Whilst macroeconomic conditions remain uncertain, we are encouraged by the underlying trading conditions and a strong Q1 performance with continued margin growth reflecting our ability to successfully manage the inflationary environment.

 

Accordingly, our full year outlook is unchanged. The Board remains confident that the benefits of recent acquisitions, continued investment in new capacity and our proven growth strategy will underpin sustainable profit growth in the coming years.

 

- ENDS -

 

 

Enquiries

 

Tim Hughes, President, Corporate Development Tel: +44 1279 436211 

Charles Armitstead, Teneo Tel: +44 7703 330 269

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKDLFLLZLEBBV
Date   Source Headline
22nd Jun 20261:31 pmRNSResults of AGM
22nd Jun 20267:00 amRNSAGM trading statement
19th Jun 20267:00 amRNSDivestment of Acrylate Monomers
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.